This trial helped redefine expectations for pharmacologic obesity treatment and provided a benchmark against which newer multi-receptor therapies are often compared
Today, you must decide which game you are playing, which theme to follow
Clinical Evidence: Reduced Cardiovascular Events Major cardiovascular outcome trials demonstrate significant benefits: LEADER trial: Semaglutide reduced major adverse cardiovascular events (MACE) by 13% compared to placebo in type 2 diabetes patients
Pregnancy or planning pregnancy : Tirzepatide should be discontinued at least one month before a planned pregnancy
As The Lancet highlights, systemic metabolic care must transcend simple prescription management
Why GLP-1Related Muscle Loss Is Adaptive Remodeling Not Muscle Wasting All effective weight-loss interventionsdietary, surgical, exercise-based, or pharmacologicreduce both fat and lean tissue to some degree